Therapeutic role of mTOR inhibitors in control of SARS-CoV-2 viral replication

Mol Biol Rep. 2023 Mar;50(3):2701-2711. doi: 10.1007/s11033-022-08188-1. Epub 2022 Dec 20.

Abstract

By the end of 2019, COVID-19 was reported in Wuhan city of China, and through human-human transmission, this virus spread worldwide and became a pandemic. Initial symptoms of the disease include fever, cough, loss of smell, taste, and shortness of breath, but a decrease in the oxygen levels in the body leads, and pneumonia may ultimately lead to the patient's death. However, the symptoms vary from patient to patient. To understand COVID-19 disease pathogenesis, researchers have tried to understand the cellular pathways that could be targeted to suppress viral replication. Thus, this article reviews the markers that could be targeted to inhibit viral replication by inhibiting the translational initiation complex/regulatory kinases and upregulating host autophagic flux that may lead to a reduction in the viral load. The article also highlights that mTOR inhibitors may act as potential inhibitors of viral replication. mTOR inhibitors such as metformin may inhibit the interaction of SARS-CoV-2 Nsp's and ORFs with mTORC1, LARP1, and 4E-BP. They may also increase autophagic flux by decreasing protein degradation via inhibition of Skp2, further promoting viral cell death. These events result in cell cycle arrest at G1 by p27, ultimately causing cell death.

Keywords: Autophagy; Coronavirus; Metformin; Skp2; mTOR inhibition.

Publication types

  • Review

MeSH terms

  • Adaptor Proteins, Signal Transducing
  • COVID-19*
  • Humans
  • MTOR Inhibitors
  • SARS-CoV-2*
  • TOR Serine-Threonine Kinases
  • Virus Replication

Substances

  • MTOR Inhibitors
  • Adaptor Proteins, Signal Transducing
  • MTOR protein, human
  • TOR Serine-Threonine Kinases